Development News Edition
Give Feedback

Aurobindo gets US health regulator approval for generic anticoagulant injection

Aurobindo Pharma today said it has received approval from the US health regulator to manufacture and market Bivalirudin injection, an anticoagulant medication, in the American market.


PTI Last Updated at 30 Jul 2018, 14:07 IST India, United States

Aurobindo Pharma today said it has received approval from the US health regulator to manufacture and market Bivalirudin injection, an anticoagulant medication, in the American market.

The company has received final approval from the US Food and Drug Administration (USFDA) for its product which is a generic version of The Medicines Company's Angiomax injection, the Hyderabad-based firm said in a statement.

The product will be launched in September 2018, it added.

According to IQVIA, the estimated market size for Bivalirudin injection stood at USD 101 million for the 12 months ending May 2018.

Aurobindo now has a total of 381 abbreviated new drug application (ANDA) approvals from the USFDA.

Shares of the company were trading 2.25 percent higher at Rs 604.50 on the BSE.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)


add banner

LEAVE COMMENT

Download our Android App on Google Play